Search

Displaying results 1401 - 1410 of 10000 in total
  1. Drug

    Sevelamer

    go.drugbank.com/drugs/DB00658
    ApprovedInvestigational

    Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.

    Products: RENALAMER 800 MG FILM TABLET, 90 ADET, SEVYAR 800 MG FILM KAPLI TABLET , 90 FILM KAPLI TABLET
  2. Drug

    Inclisiran

    go.drugbank.com/drugs/DB14901
    ApprovedInvestigational

    [L28178] Inclisiran was later approved by the FDA on December 22, 2021, for the treatment of heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease in adults … [A225953,A225958] On December 11, 2020, the European Commission (EC) granted authorization for marketing inclisiran as the first and only approved siRNA for the treatment of adults with primary hypercholesterolemia

    Products: LYPTİMZİA 284 MG/1,5 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, LEQVIO SOLUTION FOR INJECTION IN PREFILLED SYRINGE 284 MG/1.5 ML
  3. Drug

    Melperone

    go.drugbank.com/drugs/DB09224
    Investigational

    Melperone has been used for a span of greater than 30 years in the European Union [L1316]. … Recently, it has been studied as a treatment of psychosis related to Parkinson's disease [L1316].

    Products: MELPERON-NEURAX 10 MG, MELPERON-NEURAX 50 MG
  4. Drug

    Gemfibrozil

    go.drugbank.com/drugs/DB01241
    ApprovedInvestigational

    [L8525] Gemfibrozil was granted FDA approval on 21 December 1981.[L8525]

    Products: LOPID 600 MG TABLET, 30 ADET, LOPID 600 MG TABLET, 100 ADET
  5. Drug

    Elranatamab

    go.drugbank.com/drugs/DB15395
    ApprovedInvestigational

    [L47815] On August 14, 2023, the FDA granted accelerated approval to elranatamab for the treatment of multiple myeloma. … [L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437]

    Synonyms: -CHAIN) (HUMAN-MUS MUSCULUS MONOCLONAL PF-06863059 .GAMMA.2-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL PF-06863059 .KAPPA.-CHAIN, (223->217')(2Products: Elrexfio 44 mg/1,1 ml Enjeksiyonluk Çözelti, 1 ADET, Elrexfio 76 mg/1,9 ml Enjeksiyonluk Çözelti, 1 ADET
  6. Drug

    Eribulin

    go.drugbank.com/drugs/DB08871
    ApprovedInvestigational

    Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors [A7439].

    Categories: Heterocyclic Compounds, 1-RingProducts: HALAVEN 0.5 mg/ml solution for injection, Eribulin Advanz Pharma 0,44 mg/ml Injektionslösung
  7. Drug

    Omega-3 fatty acids

    go.drugbank.com/drugs/DB11133
    ApprovedInvestigationalNutraceutical

    Omega-3 fatty acids play a critical role in metabolism and cellular function and they are available as daily supplements. On September 8, 2004, the U.S.

    Mixtures: LIPOMEGA® 10, LIPOMEGA® 20Products: EPAX720 MG, INFASURF 6.0 ML
  8. Drug

    Lanadelumab

    go.drugbank.com/drugs/DB14597
    ApprovedInvestigational

    Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. … [L4537] It has been granted priority review, breakthrough therapy, and orphan drug designations for rare diseases based on the results of clinical trials.

    Products: TAKHZYRO 300 MG/2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, TAKHZYRO 300 MG/2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 2 ADET
  9. Drug

    Choriogonadotropin alfa

    go.drugbank.com/drugs/DB00097
    ApprovedInvestigational

    -13, ASN-30, SER-121, SER-127, SER-132 and SER-138 (on beta subunit). … Recombinant human chorionic gonadotropin with 2 subunits, alpha = 92 residues, beta = 145 residues, each with N-and O-linked carbohydrate moieties linked to ASN-52 and ASN-78 (on alpha subunit) and ASN

    Products: OVITRELLE 250 MCG/0,5 ML KULLANIMA HAZIR ŞIRINGADA ENJEKSİYONLUK ÇÖZELTİ, 1 ADET, Ovidrel Solution for Injection 250 mcg
  10. Drug

    Obinutuzumab

    go.drugbank.com/drugs/DB08935
    ApprovedInvestigational

    [L54521] First approved by the FDA on February 26, 2016,[L54531] obinutuzumab is used to treat chronic lymphocytic leukemia, follicular lymphoma, and lupus nephritis.[L54521] … [L54521] It was developed as a Type II anti-CD20 antibody to improve upon first-generation agents like rituximab.

    Categories: CD20 (Clusters of Differentiation 20) inhibitorsProducts: GAZYVA 1000 MG/ 40 ML CONCENTRATE FOR SOLUTION FOR INFUSION, GAZYVA ® CONCENTRADO PARA SOLUCIÓN PARA INFUSIÓN 1000 MG / VIAL 40 ML